| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000025427 |
| Receipt No. | R000029269 |
| Official scientific title of the study | Study on efficacy and safety of combination treatment with febuxostat and inosine for patients with heart failure |
| Date of disclosure of the study information | 2017/02/26 |
| Last modified on | 2017/05/09 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Study on efficacy and safety of combination treatment with febuxostat and inosine for patients with heart failure | |
| Title of the study (Brief title) | Effect of febuxostat and inosine on heart failure | |
| Region |
|
|
| Condition | ||
| Condition | heart failure | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Examine efficacy and safety of simultaneous administration of febuxostat and inosine for patients with heart failure.
|
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Difference of serum BNP between before and after the treatment |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Administration of febuxostat 20 mg and inosine 500 mg twice a day for 14 days | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with 20 to 80 years of age
2. Patients with mild or moderate heart failure 3. Those who have the capacity to consent and consented with free will, after sufficient explanation of the purpose and contents of this study, to participate in the study with written document. 4. Patients whose BNP measured within 2 months before the start of the drug administration is higher than the normal range. |
|||
| Key exclusion criteria | 1. Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug.
2. Subjects taking azathioprine or mercaptopurine 3. Subject who has or had renal function disorder. 4. Subject with a history of gout, hyperuricemia or urolithiasis. 5. Patients who changed therapeutic drugs and treatment methods within 1 month before administration of test drugs 6. Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons. |
|||
| Target sample size | 6 | |||
| Research contact person | |
| Name of lead principal investigator | Naoyuki Kamatani |
| Organization | Tsukuba International Clinical Pharmacology Clinic |
| Division name | Doctors' office |
| Address | 1-21-16 Kan-nondai Tsukuba City, Ibaraki Prefecture |
| TEL | 029-839-1150 |
| kamatani@msb.biglobe.ne.jp | |
| Public contact | |
| Name of contact person | Masanori Suzuki |
| Organization | Tsukuba International Clinical Pharmacology Clinic |
| Division name | Division for Volunteers |
| Address | 1-21-16 Kan-nondai Tsukuba City, Ibaraki Prefecture |
| TEL | 029-839-1150 |
| Homepage URL | |
| m-suzuki@tsukuba-icp.jp | |
| Sponsor | |
| Institute | Tsukuba International Clinical Pharmacology Clinic |
| Institute | |
| Department | |
| Funding Source | |
| Organization | StaGen Co. LTD |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029269 |